Ahn J D, Morishita R, Kaneda Y, Kim H J, Kim Y D, Lee H J, Lee K U, Park J Y, Kim Y H, Park K K, Chang Y C, Yoon K H, Kwon H S, Park K G, Lee I K
Department of Microbiology, Kyungpook National University, Taegu, Korea.
Gene Ther. 2004 Jun;11(11):916-23. doi: 10.1038/sj.gt.3302236.
Diabetic nephropathy is characterized by an expansion of glomerular mesangium, caused by mesangial cell proliferation and excessive accumulation of extracellular matrix (ECM) proteins, which eventually leads to glomerulosclerosis and renal failure. Activator protein-1 (AP-1), a transcription factor, is implicated in the transcriptional regulation of a wide range of genes participating in cell proliferation and ECM production. This investigation was undertaken to test the hypothesis that AP-1 plays an important role in ECM gene expression, and to develop a molecular therapeutic strategy based on decoy oligodeoxynucleotides (ODN). In this report, we show that transfection with AP-1 decoy ODN strongly inhibits high glucose- and angiotensin II-induced cell proliferation and expression of ECM genes in cultured mesangial cells in vitro. Administration of AP-1 decoy ODN into streptozotocin-induced diabetic rat kidney in vivo using the hemagglutinating virus of Japan (HVJ)-liposome method virtually abolished TGF-beta1 and plasminogen activator inhibitor-1 expression. Our results collectively indicate that AP-1 activation is crucial for mesangial cell proliferation and ECM production in response to high glucose and angiotensin II. Moreover, use of stable AP-1 decoy ODN combined with the highly effective HVJ-liposome method provides a novel potential molecular therapeutic strategy for the prevention of diabetic nephropathy.
糖尿病肾病的特征是肾小球系膜扩张,这是由系膜细胞增殖和细胞外基质(ECM)蛋白过度积累引起的,最终导致肾小球硬化和肾衰竭。激活蛋白-1(AP-1)是一种转录因子,参与多种参与细胞增殖和ECM产生的基因的转录调控。本研究旨在验证AP-1在ECM基因表达中起重要作用这一假说,并开发基于诱饵寡脱氧核苷酸(ODN)的分子治疗策略。在本报告中,我们表明用AP-1诱饵ODN转染可强烈抑制体外培养的系膜细胞中高糖和血管紧张素II诱导的细胞增殖和ECM基因表达。使用日本血凝病毒(HVJ)-脂质体方法将AP-1诱饵ODN体内注射到链脲佐菌素诱导的糖尿病大鼠肾脏中,几乎消除了转化生长因子-β1和纤溶酶原激活物抑制剂-1的表达。我们的结果共同表明,AP-1激活对于高糖和血管紧张素II诱导的系膜细胞增殖和ECM产生至关重要。此外,使用稳定的AP-1诱饵ODN结合高效的HVJ-脂质体方法为预防糖尿病肾病提供了一种新的潜在分子治疗策略。